Nephrol Dial Transplant (1999) 14: 10-15
© 1999 European Renal Association-European Dialysis and Transplant Association
Article
Healthcare systems and end-stage renal disease (ESRD) therapies—an international review: access to ESRD treatments
Division of Nephrology, Department of Medicine, University of Vienna, Austria 1 Hospital La Paz, Servicio de Nefrologia, Madrid, Spain 2 Dialysis Unit, Health Road Hospital, Ipswich, UK
Correspondence and offprint requests to: Correspondence and offprint requests to: Professor W. H. Hörl, MD, PhD, FRCP, Medizinische Universitätsklinik III, Klin. Abteilung für Nephrologie und Dialyse, Währinger Gürtel 18–20, A-1090 Wien, Austria.
Assessment of healthcare technology and economics can be used to assess the access to healthcare, its quality and efficacy as well as its cost and cost efficiency. This report addresses these issues for the provision of care for end-stage renal disease (ESRD) patients. An international comparison of access to ESRD treatment modalities was made with reference to the healthcare provider structure in a range of industrial countries. The countries were grouped into ‘public’ (Beveridge model), ‘mixed’ (Bismarck model) and ‘private’ (Private Insurance model). In ‘public’ provider countries, 20–52% of dialysis patients are treated with home therapies (haemodialysis and peritoneal dialysis), and the number of patients with renal transplants is 45–81% of all ESRD patients. In ‘mixed’ provider countries, only 9–17% of all dialysis patients are treated with home therapies, and 20–48% of ESRD patients have renal transplants. In ‘private’ provider countries, 17% of US and 6% Japanese dialysis patients are treated with home therapies. Japan has 0.3% and the US has 26% of ESRD patients who receive renal transplants. It thus seems that provider structure influences access to and choice of ESRD treatment. With a growing elderly population and longer life expectancy, there will be an increased requirement for ESRD treatments in all industrial countries. Equal access to, and quality of ESRD care in the future will require adequate funding and reimbursement strategies in a cost-constrained healthcare environment.
Keywords: healthcare; health technology; haemodialysis; peritoneal dialysis; renal transplantation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. J. Caskey, V. S. Stel, R. F. Elliott, K. J. Jager, A. Covic, A. Cusumano, C. Geue, A. Kramer, B. Stengel, and A. M. MacLeod The EVEREST study: an international collaboration NDT Plus, October 19, 2009; (2009) sfp146v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Wetmore, S. K. Rigler, J. D. Mahnken, P. Mukhopadhyay, and T. I. Shireman Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage? Nephrol. Dial. Transplant., September 7, 2009; (2009) gfp396v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-C. Yang, S.-J. Hwang, and Taiwan Society of Nephrology Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3977 - 3982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Viglino, L. Neri, S. Alloatti, G. Cabiddu, R. Cocchi, A. Limido, G. Marinangeli, R. Russo, U. Teatini, and F. P. Schena Analysis of the factors conditioning the diffusion of peritoneal dialysis in Italy Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3601 - 3605. [Abstract] [Full Text] [PDF]
|
|